Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA

Detalles Bibliográficos
Autores principales: Johansen, Pierre, Hunt, Barnaby, Iyer, Neeraj N., Dang-Tan, Tam, Pollock, Richard F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824373/
https://www.ncbi.nlm.nih.gov/pubmed/30980280
http://dx.doi.org/10.1007/s12325-019-00945-2
_version_ 1783464728042930176
author Johansen, Pierre
Hunt, Barnaby
Iyer, Neeraj N.
Dang-Tan, Tam
Pollock, Richard F.
author_facet Johansen, Pierre
Hunt, Barnaby
Iyer, Neeraj N.
Dang-Tan, Tam
Pollock, Richard F.
author_sort Johansen, Pierre
collection PubMed
description
format Online
Article
Text
id pubmed-6824373
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-68243732019-11-06 Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA Johansen, Pierre Hunt, Barnaby Iyer, Neeraj N. Dang-Tan, Tam Pollock, Richard F. Adv Ther Correction Springer Healthcare 2019-04-12 2019 /pmc/articles/PMC6824373/ /pubmed/30980280 http://dx.doi.org/10.1007/s12325-019-00945-2 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Correction
Johansen, Pierre
Hunt, Barnaby
Iyer, Neeraj N.
Dang-Tan, Tam
Pollock, Richard F.
Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
title Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
title_full Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
title_fullStr Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
title_full_unstemmed Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
title_short Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
title_sort correction to: a relative cost of control analysis of once-weekly semaglutide versus exenatide extended-release and dulaglutide for bringing patients to hba1c and weight loss treatment targets in the usa
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824373/
https://www.ncbi.nlm.nih.gov/pubmed/30980280
http://dx.doi.org/10.1007/s12325-019-00945-2
work_keys_str_mv AT johansenpierre correctiontoarelativecostofcontrolanalysisofonceweeklysemaglutideversusexenatideextendedreleaseanddulaglutideforbringingpatientstohba1candweightlosstreatmenttargetsintheusa
AT huntbarnaby correctiontoarelativecostofcontrolanalysisofonceweeklysemaglutideversusexenatideextendedreleaseanddulaglutideforbringingpatientstohba1candweightlosstreatmenttargetsintheusa
AT iyerneerajn correctiontoarelativecostofcontrolanalysisofonceweeklysemaglutideversusexenatideextendedreleaseanddulaglutideforbringingpatientstohba1candweightlosstreatmenttargetsintheusa
AT dangtantam correctiontoarelativecostofcontrolanalysisofonceweeklysemaglutideversusexenatideextendedreleaseanddulaglutideforbringingpatientstohba1candweightlosstreatmenttargetsintheusa
AT pollockrichardf correctiontoarelativecostofcontrolanalysisofonceweeklysemaglutideversusexenatideextendedreleaseanddulaglutideforbringingpatientstohba1candweightlosstreatmenttargetsintheusa

Ejemplares similares